Suppr超能文献

左旋多巴诱导异动症动物模型中用于药物评估的系统水平神经生理状态特征

Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia.

作者信息

Tamtè Martin, Brys Ivani, Richter Ulrike, Ivica Nedjeljka, Halje Pär, Petersson Per

机构信息

Integrative Neurophysiology and Neurotechnology, Neuronano Research Center, Department of Experimental Medical Sciences, Lund University, Lund, Sweden.

Integrative Neurophysiology and Neurotechnology, Neuronano Research Center, Department of Experimental Medical Sciences, Lund University, Lund, Sweden

出版信息

J Neurophysiol. 2016 Mar;115(3):1713-29. doi: 10.1152/jn.00868.2015. Epub 2016 Jan 6.

Abstract

Disorders affecting the central nervous system have proven particularly hard to treat, and disappointingly few novel therapies have reached the clinics in recent decades. A better understanding of the physiological processes in the brain underlying various symptoms could therefore greatly improve the rate of progress in this field. We here show how systems-level descriptions of different brain states reliably can be obtained through a newly developed method based on large-scale recordings in distributed neural networks encompassing several different brain structures. Using this technology, we characterize the neurophysiological states associated with parkinsonism and levodopa-induced dyskinesia in a rodent model of Parkinson's disease together with pharmacological interventions aimed at reducing dyskinetic symptoms. Our results show that the obtained electrophysiological data add significant information to conventional behavioral evaluations and hereby elucidate the underlying effects of treatments in greater detail. Taken together, these results potentially open up for studies of neurophysiological mechanisms underlying symptoms in a wide range of neurological and psychiatric conditions that until now have been very hard to investigate in animal models of disease.

摘要

事实证明,影响中枢神经系统的疾病特别难以治疗,近几十年来令人失望的是,很少有新疗法进入临床。因此,更好地理解大脑中各种症状背后的生理过程,可能会大大提高该领域的进展速度。我们在此展示了如何通过一种新开发的方法,基于在包含几种不同脑结构的分布式神经网络中的大规模记录,可靠地获得不同脑状态的系统级描述。利用这项技术,我们在帕金森病的啮齿动物模型中,将与帕金森症和左旋多巴诱导的运动障碍相关的神经生理状态,与旨在减轻运动障碍症状的药物干预一起进行了表征。我们的结果表明,所获得的电生理数据为传统行为评估增添了重要信息,从而更详细地阐明了治疗的潜在效果。综上所述,这些结果可能为研究广泛的神经和精神疾病症状背后的神经生理机制开辟道路,而这些疾病迄今为止在疾病动物模型中一直很难进行研究。

相似文献

1
Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia.
J Neurophysiol. 2016 Mar;115(3):1713-29. doi: 10.1152/jn.00868.2015. Epub 2016 Jan 6.
4
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Mov Disord. 2013 Nov;28(13):1838-46. doi: 10.1002/mds.25561. Epub 2013 Jul 12.
5
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
Nat Rev Neurosci. 2001 Aug;2(8):577-88. doi: 10.1038/35086062.
6
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.
7
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Mov Disord. 2016 Apr;31(4):501-11. doi: 10.1002/mds.26475. Epub 2016 Feb 12.
10
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Fundam Clin Pharmacol. 2011 Oct;25(5):608-18. doi: 10.1111/j.1472-8206.2010.00883.x. Epub 2010 Nov 16.

引用本文的文献

3
Pathological cell assembly dynamics in a striatal MSN network model.
Front Comput Neurosci. 2024 Jun 6;18:1410335. doi: 10.3389/fncom.2024.1410335. eCollection 2024.
4
Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson's disease psychosis.
Neurotherapeutics. 2024 Mar;21(2):e00334. doi: 10.1016/j.neurot.2024.e00334. Epub 2024 Feb 16.
5
Distinctive Effects of D1 and D2 Receptor Agonists on Cortico-Basal Ganglia Oscillations in a Rodent Model of L-DOPA-Induced Dyskinesia.
Neurotherapeutics. 2023 Jan;20(1):304-324. doi: 10.1007/s13311-022-01309-5. Epub 2022 Nov 7.
6
Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.
Exp Neurol. 2021 Jun;340:113670. doi: 10.1016/j.expneurol.2021.113670. Epub 2021 Mar 2.
9
On the neuronal circuitry mediating L-DOPA-induced dyskinesia.
J Neural Transm (Vienna). 2018 Aug;125(8):1157-1169. doi: 10.1007/s00702-018-1886-0. Epub 2018 Apr 27.

本文引用的文献

1
Characterization of long-term motor deficits in the 6-OHDA model of Parkinson's disease in the common marmoset.
Behav Brain Res. 2015 Sep 1;290:90-101. doi: 10.1016/j.bbr.2015.04.037. Epub 2015 Apr 28.
2
Therapeutic deep brain stimulation reduces cortical phase-amplitude coupling in Parkinson's disease.
Nat Neurosci. 2015 May;18(5):779-86. doi: 10.1038/nn.3997. Epub 2015 Apr 13.
3
Cell-based screening: extracting meaning from complex data.
Neuron. 2015 Apr 8;86(1):160-74. doi: 10.1016/j.neuron.2015.02.023.
4
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
Brain. 2015 Apr;138(Pt 4):963-73. doi: 10.1093/brain/awu409. Epub 2015 Feb 10.
6
Design of a high-density multi-channel electrode for multi-structure parallel recordings in rodents.
Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:393-6. doi: 10.1109/EMBC.2014.6943611.
7
Spinal cord stimulation alleviates motor deficits in a primate model of Parkinson disease.
Neuron. 2014 Nov 19;84(4):716-722. doi: 10.1016/j.neuron.2014.08.061. Epub 2014 Oct 30.
8
Functional correlates of exaggerated oscillatory activity in basal ganglia output in hemiparkinsonian rats.
Exp Neurol. 2014 Nov;261:563-77. doi: 10.1016/j.expneurol.2014.07.010. Epub 2014 Jul 30.
10
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Neuroscience. 2014 Apr 18;265:245-52. doi: 10.1016/j.neuroscience.2014.01.042. Epub 2014 Jan 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验